ear-10q_20210331.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 10-Q

 

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission File Number: 001-39616

 

 

Eargo, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

27-3879805

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

1600 Technology Drive, 6th Floor

San Jose, California 95110

95110

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (650) 351-7700

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

EAR

 

The Nasdaq Global Select Stock Market

 

 

 

 

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

  

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

  

Smaller reporting company

 

 

 

 

 

 

 

 

Emerging growth company

 

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes      No  

As of May 5, 2021, the registrant had 38,731,538 shares of common stock, par value $0.0001 outstanding.

 

 

 

 


 

 

Table of Contents

 

 

 

 

Page

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

1

PART I.

FINANCIAL INFORMATION

 

2

Item 1.

Financial Statements (Unaudited)

 

2

 

Condensed Consolidated Balance Sheets

 

2

 

Condensed Consolidated Statements of Operations and Comprehensive Loss

 

3

 

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit

 

4

 

Condensed Consolidated Statements of Cash Flows

 

5

 

Notes to Unaudited Condensed Consolidated Financial Statements

 

6

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

14

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

 

21

Item 4.

Controls and Procedures

 

22

PART II.

OTHER INFORMATION

 

23

Item 1.

Legal Proceedings

 

23

Item 1A.

Risk Factors

 

23

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

 

56

Item 3.

Defaults Upon Senior Securities

 

56

Item 4.

Mine Safety Disclosures

 

56

Item 5.

Other Information

 

56

Item 6.

Exhibits

 

57

 

 

 

i


 

 

Special note regarding forward-looking statements

This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks, uncertainties and assumptions. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

 

our ability to attract and retain customers;

 

our expectations concerning additional orders by existing customers;

 

our expectations regarding the potential market size and size of the potential consumer populations for our products and any future products, including our ability to maintain or increase insurance coverage of Eargo hearing aids;

 

our ability to release new hearing aids and the anticipated features of any such hearing aids;

 

developments and projections relating to our competitors and our industry, including competing products;

 

our ability to maintain our competitive technological advantages against new entrants in our industry;

 

the pricing of our hearing aids;

 

our expectations regarding the ability to make certain claims related to the performance of our hearing aids relative to competitive products;

 

our expectations with regard to changes in the regulatory landscape for hearing aid devices, including the implementation of the pending over-the-counter hearing aid pathway regulatory framework;

 

our commercialization and marketing capabilities and expectations;

 

our relationships with, and the capabilities of, our component manufacturers, suppliers and freight carriers;

 

the implementation of our business model and strategic plans for our business and products and technology;

 

the scope of protection we are able to establish and maintain for intellectual property rights covering our products, including the projected terms of patent protection;

 

our ability to effectively manage our growth;

 

our expectations regarding the time during which we will be an emerging growth company under the JOBS Act;

 

our estimates regarding the COVID-19 pandemic, including but not limited to, its duration and its impact on our business and results of operations;

 

estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our ability to obtain additional capital; and

 

our future financial performance.

We have based these forward-looking statements largely on our current expectations, estimates, forecasts and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. You should refer to the section titled “Risk Factors” for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

1


 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

Eargo, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands, except share and per share amounts)

 

 

 

March 31,

 

 

December 31,

 

 

 

2021

 

 

2020

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

201,624

 

 

$

212,185

 

Accounts receivable, net

 

 

5,339

 

 

 

3,793

 

Inventories

 

 

2,463

 

 

 

2,739

 

Prepaid expenses and other current assets

 

 

3,175

 

 

 

3,740

 

Total current assets

 

 

212,601

 

 

 

222,457

 

Operating lease right-of-use assets

 

 

1,218

 

 

 

1,079

 

Property and equipment, net

 

 

8,924

 

 

 

8,034

 

Other assets

 

 

1,086

 

 

 

1,062

 

Total assets

 

$

223,829

 

 

$

232,632

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

6,604

 

 

$

6,020

 

Accrued expenses

 

 

10,992

 

 

 

13,909

 

Other current liabilities

 

 

3,950

 

 

 

2,448

 

Deferred revenue, current portion

 

 

173

 

 

 

311

 

Lease liability, current portion

 

 

1,050

 

 

 

1,030

 

Total current liabilities

 

 

22,769

 

 

 

23,718

 

Lease liability, noncurrent portion

 

 

263

 

 

 

166

 

Long-term debt, noncurrent portion

 

 

14,940

 

 

 

14,837

 

Total liabilities

 

 

37,972

 

 

 

38,721

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.0001 par value per share; 5,000,000 shares authorized

   as of March 31, 2021 and December 31, 2020, respectively; zero shares

   issued and outstanding as of March 31, 2021 and December 31, 2020,

   respectively

 

 

 

 

 

 

Common stock; $0.0001 par value; 110,000,000 shares authorized

   as of March 31, 2021 and December 31, 2020, respectively; 38,298,068

   and 38,246,601 shares issued and outstanding as of March 31, 2021

   and December 31, 2020, respectively

 

 

4

 

 

 

4

 

Additional paid in capital

 

 

398,532

 

 

 

392,965

 

Accumulated deficit

 

 

(212,679

)

 

 

(199,058

)

Total stockholders’ equity

 

 

185,857

 

 

 

193,911

 

Total liabilities and stockholders’ equity

 

$

223,829

 

 

$

232,632

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

2


 

Eargo, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except share and per share amounts)

 

 

 

Three months ended

March 31,

 

 

 

2021

 

 

2020

 

Revenue, net

 

$

22,048

 

 

$

12,669

 

Cost of revenue

 

 

6,297

 

 

 

4,656

 

Gross profit

 

 

15,751

 

 

 

8,013

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

 

4,778

 

 

 

2,809

 

Sales and marketing

 

 

16,855

 

 

 

10,859

 

General and administrative

 

 

7,487

 

 

 

6,078

 

Total operating expenses

 

 

29,120

 

 

 

19,746

 

Loss from operations

 

 

(13,369

)

 

 

(11,733

)

Other income (expense), net:

 

 

 

 

 

 

 

 

Interest income

 

 

11

 

 

 

21

 

Interest expense

 

 

(263

)

 

 

(266

)

Other income (expense), net

 

 

 

 

 

240

 

Total other income (expense), net

 

 

(252

)

 

 

(5

)

Loss before income taxes

 

 

(13,621

)

 

 

(11,738

)

Income tax provision

 

 

 

 

 

 

Net loss and comprehensive loss

 

$

(13,621

)

 

$

(11,738

)

Net loss attributable to common stockholders, basic and

   diluted

 

$

(13,621

)

 

$

(11,738

)

Net loss per share attributable to common stockholders,

   basic and diluted

 

$

(0.36

)

 

$

(43.76

)

Weighted-average shares used in computing net loss per share

   attributable to common stockholders, basic and diluted

 

 

38,283,360

 

 

 

268,214

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3


 

Eargo, Inc.

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)

(Unaudited)

(In thousands, except share amounts)

 

 

 

Convertible preferred stock

 

 

 

Common stock

 

 

Additional

paid-in

 

 

Accumulated

 

 

Total

stockholders’

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

capital

 

 

deficit

 

 

equity

 

Balance December 31, 2020

 

 

 

 

$

 

 

 

 

38,246,601

 

 

$

4

 

 

$

392,965

 

 

$

(199,058

)

 

$

193,911

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5,449

 

 

 

 

 

 

5,449

 

Exercise of stock options

 

 

 

 

 

 

 

 

 

51,467

 

 

 

 

 

 

118

 

 

 

 

 

 

118

 

Net loss and comprehensive

   loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(13,621

)

 

 

(13,621

)

Balance March 31, 2021

 

 

 

 

$

 

 

 

 

38,298,068

 

 

$

4

 

 

$

398,532

 

 

$

(212,679

)

 

$

185,857

 

 

 

 

 

Convertible preferred stock

 

 

 

Common stock

 

 

Additional

paid-in

 

 

Accumulated

 

 

Total

stockholders’

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

capital

 

 

deficit

 

 

deficit

 

Balance December 31, 2019

 

 

11,825,812

 

 

$

152,880

 

 

 

 

265,943

 

 

$

 

 

$

3,100

 

 

$

(159,203

)

 

$

(156,103

)

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

525

 

 

 

 

 

 

525

 

Exercise of stock options

 

 

 

 

 

 

 

 

 

4,188

 

 

 

 

 

 

8

 

 

 

 

 

 

8

 

Net loss and comprehensive

   loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(11,738

)

 

 

(11,738

)

Balance March 31, 2020

 

 

11,825,812

 

 

$

152,880

 

 

 

 

270,131

 

 

$

 

 

$

3,633

 

 

$

(170,941

)

 

$

(167,308

)

 

4


 

 

Eargo, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

 

 

 

Three months ended March 31,

 

 

 

2021

 

 

2020

 

Operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(13,621

)

 

$

(11,738

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

735

 

 

 

565

 

Stock-based compensation

 

 

5,131

 

 

 

525

 

Non-cash interest expense and amortization of debt discount

 

 

103

 

 

 

157

 

Non-cash operating lease expense

 

 

295

 

 

 

274

 

Bad debt expense

 

 

62

 

 

 

253

 

Change in fair value of financial instruments

 

 

 

 

 

(243

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(1,608

)

 

 

129

 

Inventories

 

 

276

 

 

 

79

 

Prepaid expenses and other current assets

 

 

565

 

 

 

(3

)

Other assets

 

 

(24

)

 

 

1,089

 

Accounts payable

 

 

715

 

 

 

1,143

 

Accrued expenses

 

 

(2,985

)

 

 

(1,385

)

Other current liabilities

 

 

1,502

 

 

 

(3

)

Deferred revenue

 

 

(138

)

 

 

23

 

Operating lease liabilities

 

 

(317

)

 

 

(287

)

Other liabilities

 

 

 

 

 

(125

)

Net cash used in operating activities

 

 

(9,309

)

 

 

(9,547

)

Investing activities:

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(296

)

 

 

(219

)

Capitalized software development costs

 

 

(1,074

)

 

 

(1,005

)

Net cash used in investing activities

 

 

(1,370

)

 

 

(1,224

)

Financing activities:

 

 

 

 

 

 

 

 

Proceeds from stock options exercised

 

 

118

 

 

 

8

 

Proceeds from issuance of convertible notes, net of issuance costs

 

 

 

 

 

8,845

 

Debt repayments

 

 

 

 

 

(1,200

)

Net cash provided by financing activities

 

 

118

 

 

 

7,653

 

Net decrease in cash and cash equivalents and restricted cash

 

 

(10,561

)

 

 

(3,118

)

Cash and cash equivalents and restricted cash at beginning of period

 

 

212,185

 

 

 

13,384

 

Cash and cash equivalents and restricted cash at end of period

 

$

201,624

 

 

$

10,266

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

 

 

Cash paid for taxes

 

$

176

 

 

$

 

Cash paid for interest

 

$

159

 

 

$

110

 

Non-cash operating activities:

 

 

 

 

 

 

 

 

Lease liability obtained in exchange for right-of-use asset

 

$

434

 

 

$

2,392

 

Non-cash investing and financing activities:

 

 

 

 

 

 

 

 

Property and equipment and capitalized software costs in accounts payable and accrued liabilities

 

$

330

 

 

$

308

 

Stock-based compensation included in capitalized software costs

 

$

318

 

 

$

 

Convertible preferred stock issuance costs included in accounts payable

 

$

600

 

 

$

 

Derivative liability in connection with issuance of convertible promissory notes on issuance

 

$

 

 

$

2,535

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

5


 

 

Eargo, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

1. Description of business

Eargo, Inc. (the “Company”) is a medical device company dedicated to improving the quality of life of people with hearing loss. The Eargo solution was developed to create a hearing aid that consumers actually want to use. The Company’s innovative product and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility and cost.

Liquidity

The Company has incurred losses and negative cash flows from operations since its inception and management expects to incur additional substantial losses in the foreseeable future. As of March 31, 2021, the Company had cash and cash equivalents of $201.6 million and an accumulated deficit of $212.7 million.

The Company believes that its existing cash and cash equivalents as of March 31, 2021 will be sufficient for the Company to continue as a going concern for at least one year from the date these unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (“SEC”). The Company’s future capital requirements will depend on many factors, including its growth rate, the timing and extent of its spending to support research and development activities and the timing and cost of establishing additional sales and marketing capabilities.

2. Summary of significant accounting policies

Basis of presentation and principles of consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and applicable rules and regulations SEC regarding interim financial reporting of Eargo, Inc. and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated.

These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s consolidated financial position, results of operations and cash flows. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2020 included herein was derived from the audited consolidated financial statements as of that date. The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 16, 2021.

Use of estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions, and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions made in the accompanying unaudited condensed consolidated financial statements include, but are not limited to, allowance for sales returns, the fair value of lease liabilities, the fair value of equity securities, the fair value of financial instruments, the allowance for doubtful accounts, the net realizable value of inventory, the useful lives of long-lived assets, accrued product warranty reserve, certain other accruals and recoverability of the Company’s net deferred tax assets and the related valuation allowance. Management periodically evaluates its estimates, which are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates.

Significant accounting policies

There have been no significant changes to the accounting policies during the three months ended March 31, 2021, as compared to the significant accounting policies described in Note 2 of the “Notes to Consolidated Financial Statements” in the Company’s audited consolidated financial statements included in the Annual Report on Form 10-K, except as discussed below.

6


Eargo, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

 

Concentration of credit risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of demand deposit accounts, money market accounts and accounts receivable, including credit card receivables. The Company maintains its cash and cash equivalents, which may, at times, exceed federally insured limits, with financial institutions of high credit standing. As of March 31, 2021, the Company has not experienced any losses on its deposit accounts and money market accounts. As of March 31, 2021, the Company does not believe there is significant financial risk from nonperformance by the issuers of the Company’s deposit accounts and money market accounts.

Approximately 57% and 45% of the Company’s gross accounts receivable are related to reimbursement from a single insurance company as of March 31, 2021 and December 31, 2020, respectively.

Accounts receivable, net

Accounts receivable represents amounts due from third-party institutions for credit card and debit card transactions and trade accounts receivable. Accounts receivable are recorded at invoiced amounts, net of allowances for doubtful accounts. The allowance for doubtful accounts is based on the Company’s assessment of the collectibility of accounts. Management regularly reviews the adequacy of the allowance for doubtful accounts by considering the age of each outstanding invoice, each customer’s expected ability to pay, and the collection history with each customer, when applicable, to determine whether a specific allowance is appropriate. As of March 31, 2021 and December 31, 2020, the Company recorded an allowance for doubtful accounts of $1.6 million and $1.9 million, respectively. The allowance for doubtful accounts charges are recorded as a component of general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss.

Revenue recognition

The Company’s revenue is generated from the sale of products (hearing aid systems and related accessories) and services (extended warranties). These products and services are primarily sold directly to customers through the Eargo website and the Company sales representatives.

Under ASC 606, revenue is recognized when promised goods or services are transferred to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services by following a five step process: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.

Identify the contract with a customer. The Company generally considers completion of an Eargo sales order (which requires customer acceptance of the Company’s click-through terms and conditions for website sales and authorization of payment through credit card or another form of payment for sales made over the phone) as a customer contract provided that collection is considered probable. For payments that are not made upfront by credit card, the Company assesses insurance eligibility or customer creditworthiness based on credit checks, payment history, and/or other circumstances. For payments involving insurance payors, the Company validates customer eligibility and reimbursement amounts prior to shipping the product.

Identify the performance obligations in the contract. Product performance obligations include hearing aid systems and related accessories and service performance obligations include extended warranty coverage. The Company also offers customers a one-time replacement of certain components of the hearing aid system for a fee (i.e., “loss and damage policy”), which represents an option with material right. However, as the historical redemption rate under the policy has been low, the option is not accounted for as a separate performance obligation. The Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer.

The Company has elected to treat shipping and handling activities performed after a customer obtains control of products as a fulfillment activity.

Determine the transaction price and allocation to performance obligations. The transaction price in the Company’s customer contracts consists of both fixed and variable consideration. Fixed consideration includes amounts to be contractually billed to the customer while variable consideration includes the 45-day right of return that applies to all products. To estimate product returns, the Company analyzes historical return levels, current economic trends, and changes in customer demand. Based on this information, the Company reserves a percentage of product sale revenue and accounts for the estimated impact as a reduction in the transaction price.

Allocate the transaction price to the performance obligations in the contract. For contracts that contain multiple performance obligations, the Company allocates the transaction price to the performance obligations on a relative standalone selling price basis.

7


Eargo, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

 

Standalone selling prices are based on multiple factors including, but not limited to, historical discounting trends for products and services, gross margin objectives, internal costs, competitor pricing strategies, and industry technology lifecycles.

Recognize revenue when or as the Company satisfies a performance obligation. Revenue for products (hearing aid systems and related accessories) is recognized at a point in time, which is generally upon shipment. Revenue for services (extended warranty) is recognized over time on a ratable basis over the warranty period.

Contract costs

The Company applies the practical expedient to recognize the incremental costs of obtaining a contract as expense when incurred if the amortization period would be one year or less. These incremental costs include processing fees paid to third-party financing vendors, who provide the Company’s customers with the option to finance their purchases. If a customer elects to utilize this service, the Company receives a non-recourse upfront payment for the product sold, less processing fee withheld by the financing vendor. These processing fees are recognized in cost of revenue in the condensed consolidated statements of operations and comprehensive loss as incurred.

Net loss per share attributable to common stockholders

The Company follows the two-class method when computing net loss per share in periods in which shares that meet the definition of participating securities are outstanding. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.

Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive securities. Diluted net income loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and common share equivalents of potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, convertible preferred stock, convertible notes, convertible preferred stock warrants and common stock options are considered to be potentially dilutive securities.

Recent accounting pronouncements not yet adopted

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. This new standard is effective for the Company in the fiscal year beginning January 1, 2023 and must be adopted using a modified retrospective approach, with certain exceptions. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which is intended to simplify the accounting for income taxes. This standard removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing standards to improve consistent application. This new standard is effective for the Company in the fiscal year beginning January 1, 2022. An entity that elects early adoption must adopt all the amendments in the same period. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements.

3. Fair value measurements

There were no financial assets and liabilities outstanding that were remeasured at fair value on a recurring basis as of March 31, 2021 or December 31, 2020.

The carrying amounts reflected in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The fair value of the Company’s outstanding term loan is estimated using the net present value of the payments, discounted at an interest rate that is consistent with a market interest rate. The fair value of the outstanding term loan approximates the carrying amount as the term loan bears a floating rate that approximates the market interest rate.

8


Eargo, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

 

4. Balance sheet components

Inventories

Inventories consist primarily of raw materials related to component parts and finished goods. The following is a summary of the Company’s inventories by category:

 

 

 

March 31,

 

 

December 31,

 

 

 

2021

 

 

2020

 

 

 

(in thousands)

 

Raw materials

 

$

946

 

 

$

853

 

Finished goods

 

 

1,517

 

 

 

1,886

 

Total inventories

 

$

2,463

 

 

$

2,739

 

Property and equipment, net

Property and equipment, net, consists of the following:

 

 

 

March 31,

 

 

 

 

 

December 31,

 

 

 

2021

 

 

 

 

 

2020

 

 

 

(in thousands)

 

Capitalized software

 

$

8,188

 

 

 

 

 

$

6,744

 

Tools and lab equipment

 

 

4,607

 

 

 

 

 

 

4,426

 

Furniture and fixtures

 

 

906

 

 

 

 

 

 

906

 

Leasehold improvements

 

 

757

 

 

 

 

 

 

757

 

Computer and equipment

 

 

288

 

 

 

 

 

 

288

 

 

 

 

14,746

 

 

 

 

 

 

13,121

 

Less accumulated depreciation and amortization

 

 

(5,822

)

 

 

 

 

 

(5,087

)

Total property and equipment, net

 

$

8,924

 

 

 

 

 

$

8,034

 

Depreciation and amortization for the three months ended March 31, 2021 and 2020 amounted to $0.7 million and $0.6 million, respectively, which includes amortization of capitalized software costs of $0.2 million and $0.2 million, respectively.

Accrued expenses

Accrued expenses consist of the following:

 

 

 

March 31,

 

 

December 31,

 

 

 

2021

 

 

2020

 

 

 

(in thousands)

 

Allowance for sales returns

 

$

2,939

 

 

$

4,326

 

Accrued compensation

 

 

3,531

 

 

 

5,861

 

Accrued vendor costs

 

 

790

 

 

 

751

 

Refunds due to customers

 

 

745

 

 

 

581

 

Accrued warranty reserve

 

 

2,987

 

 

 

2,390

 

Total accrued expenses

 

$

10,992

 

 

$

13,909

 

 

Accrued warranty reserve

The accrued warranty reserve consists of the following activity:

 

 

 

Three months ended March 31,

 

 

Year ended

December 31,

 

 

 

2021

 

 

2020

 

 

 

(in thousands)

 

Accrued warranty reserve, beginning balance

 

$

2,390

 

 

$

450

 

Charged to cost of revenue

 

 

950

 

 

 

3,178

 

Utilization of accrued warranty reserve

 

 

(353

)

 

 

(1,238

)

Accrued warranty reserve, ending balance

 

$

2,987

 

 

$

2,390

 

9


Eargo, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

 

 

 

5. Commitments and contingencies

Operating leases

The Company has entered into non-cancelable operating leases for its offices. These leases generally contain scheduled rent increases and renewal options, which are not included in the determination of lease term unless the Company is reasonably certain that the renewal option would be exercised.

In February 2021, the Company amended the operating lease for its Nashville, Tennessee office to extend the term of the initial lease through March 2023 and reduce the size of office space leased. This extension was accounted for as a lease modification and the Company recorded an increase to the right-of-use (“ROU”) asset and lease liability of $0.4 million at the time of the amendment.

As of March 31, 2021, the Company recorded an aggregate ROU asset of $1.2 million and an aggregate lease liability of $1.3 million in the accompanying condensed consolidated balance sheet. The ROU asset and corresponding lease liability were estimated using a weighted-average incremental borrowing rate of 7.1%. The weighted-average remaining lease term is 1.3 years.

For the three months ended March 31, 2021, the Company incurred $0.3 million of operating lease costs. Variable lease payments for operating expenses and costs related to short-term leases were immaterial for the three months ended March 31, 2021.

As of March 31, 2021, undiscounted future minimum lease payments due under the non-cancelable operating leases are as follows:

 

 

 

Operating

leases

 

 

 

(in thousands)

 

Remainder of 2021

 

$

910

 

2022

 

 

401

 

2023

 

 

59

 

Total minimum future lease payments

 

 

1,370

 

Present value adjustment for minimum lease commitments

 

 

(57

)

Total lease liability

 

$

1,313

 

 

Litigation

The Company may become involved in legal proceedings in the ordinary course of its business. The Company does not believe that any lawsuits or claims currently pending against it, individually or in the aggregate, are material, or will have a material adverse effect on its financial condition, results of operations or cash flows. The Company is subject to review from federal and state taxing authorities in order to validate the amounts of income, sales and/or use taxes which have been claimed and remitted. The Company has estimated exposure and established reserves for its estimated sales tax audit liability.

In the normal course of business, the Company may agree to indemnify third parties with whom it enters into contractual relationships, including customers, lessors, and parties to other transactions with the Company, with respect to certain matters. The Company has agreed, under certain conditions, to hold these third parties harmless against specified losses, such as those arising from a breach of representations or covenants, other third-party claims that the Company’s products, when used for their intended purposes, infringe the intellectual property rights of such other third parties, or other claims made against certain parties. It is not possible to determine the maximum potential amount of liability under these indemnification obligations due to the Company’s limited history of prior indemnification claims and the unique facts and circumstances that are likely to be involved in each particular claim.

6. Debt obligations

2018 Loan Agreement

In June 2018, the Company entered into a Loan and Security Agreement (the “2018 Loan Agreement”) with Silicon Valley Bank. Under the terms of the 2018 Loan Agreement, Silicon Valley Bank made available to the Company term loans in an aggregate principal amount of $12.5 million and the Company borrowed $5.0 million in October 2018, $1.0 million in November 2018 and $1.0 million in December 2018.

In connection with the execution of the 2018 Loan Agreement, the Company issued warrants to purchase 30,173 shares of Series C convertible preferred stock. The estimated fair value of the warrants at issuance was recorded as a discount on the loan and is amortized to interest expense over the term of the agreement using the effective interest method.

10


Eargo, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

 

Amendments to the 2018 Loan Agreement

In January 2019, the Company executed the First Amendment to the Loan and Security Agreement, which extended the interest-only period for all borrowings under the agreement until January 2020. No other terms were amended. In June 2019, the Company borrowed an additional $5.0 million to increase the total principal balance to $12.0 million. In connection with the June 2019 borrowing, the Company issued Silicon Valley Bank warrants to purchase 14,999 shares of Series C convertible preferred stock.

In May 2020, the Company executed the Second Amendment to its Loan and Security Agreement, which deferred the principal payments due between May 2020 and July 2020 such that the deferred amounts will be repaid in equal monthly payments that started in August 2020 through the scheduled maturity of the loan in June 2022. The amendment was accounted for as a modification.

In September 2020, the Company executed the Third Amendment to the Loan and Security Agreement (the “Third Amendment”), under which Silicon Valley Bank made available to the Company additional term loans in an aggregate principal amount of $20.0 million through December 31, 2020. The Company borrowed $15.0 million in September 2020 and used $10.2 million of the proceeds to repay the outstanding balance of $9.5 million and final payment fee of $0.7 million, or 6.0% of the original aggregate principal amount, on the existing term loan. The Company’s ability to borrow any additional principal under the Third Amendment expired unused on December 31, 2020.

The term loan under the Third Amendment matures in September 2024 with interest-only monthly payments until January 2022, which was extended to July 2022 upon the completion of the Company’s initial public offering (“IPO”) in October 2020. The term loan accrues interest at a per annum rate equal to the Wall Street Journal prime rate plus 1.0% (4.25% as of March 31, 2021) and includes a final payment fee equal to 6.25% of the original aggregate principal amount. In connection with the execution of the Third Amendment, the Company issued Silicon Valley Bank a warrant to purchase 53,487 shares of Series E convertible preferred stock. The amendment was accounted for as a modification.

Borrowings under the Third Amendment are collateralized by substantially all the assets of the Company, excluding intellectual property (but including rights to payment and proceeds thereof). The Third Amendment contains customary affirmative and restrictive covenants, including with respect to the Company’s ability to enter into fundamental transactions, incur additional indebtedness, grant liens, pay any dividend or make any distributions to its holders, make investments, merge or consolidate with any other person or engage in transactions with the Company’s affiliates, but do not include any financial covenants. The Company was in compliance with all of the covenants as of March 31, 2021.

As of March 31, 2021, outstanding principal on the term loan and accrual for the final payment fee amounted to $15.2 million. During the three months ended March 31, 2021 and 2020, the Company recognized interest expense related to the term loans of $0.3 million and $0.2 million, respectively, which is inclusive of amortization of debt discount. The effective interest rate was 7.12% as of March 31, 2021.

7. Stock-based compensation

Total stock-based compensation is as follows:

 

 

 

Three months ended March 31,

 

 

 

2021

 

 

2020

 

 

 

(in thousands)

 

Cost of revenue

 

$

186

 

 

$

5

 

Research and development

 

 

1,067

 

 

 

164

 

Sales and marketing

 

 

1,856

 

 

 

123

 

General and administrative

 

 

2,022

 

 

 

233

 

Total stock-based compensation

 

$

5,131

 

 

$

525

 

 

Stock-based compensation costs capitalized as part of capitalized software costs was $0.3 million during the three months ended March 31, 2021. No such costs were capitalized during the three months ended March 31, 2020.

11


Eargo, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

 

Determination of fair value

The estimated grant-date fair value of the Company’s stock-based awards was calculated using the Black-Scholes option pricing model, based on the following assumptions:

 

 

 

Three months ended March 31,

Valuation assumptions:

 

2021

 

2020

Expected volatility

 

56.8%-57.2%

 

59.6%-60.1%

Expected term

 

5.8-6.7 years

 

5.8-6.1 years

Risk-free interest rate

 

0.62%-1.09%

 

1.18%-1.20%

Dividend yield

 

 

 

Equity incentive plans

As of March 31, 2021, 6,053,922 shares of common stock are issuable upon the exercise of outstanding awards under the 2010 Equity Incentive Plan. As of March 31, 2021, the Company had reserved 6,877,638 shares of common stock for issuance under the 2020 Equity Incentive Plan (the “2020 Plan”), of which 6,359,105 are available for issuance in connection with grants of future awards.

Stock option activity for the three months ended March 31, 2021 is set forth below:

 

 

 

Number of

shares

 

 

Weighted

average

exercise

price

 

 

Weighted

average

remaining

contractual

term

 

 

Aggregate

intrinsic value

 

 

 

 

 

 

 

 

 

 

 

(in years)

 

 

(in thousands)

 

Balance December 31, 2020

 

 

6,468,844

 

 

$

2.78

 

 

 

8.77

 

 

$

271,944

 

Grants

 

 

184,420

 

 

 

55.03

 

 

 

 

 

 

 

 

 

Exercises

 

 

(51,467

)

 

 

2.29

 

 

 

 

 

 

 

 

 

Cancelled/forfeited

 

 

(282,642

)

 

 

2.86

 

 

 

 

 

 

 

 

 

Balance March 31, 2021

 

 

6,319,155

 

 

$

4.31

 

 

 

8.55

 

 

$

302,019

 

Vested and exercisable at March 31, 2021

 

 

1,960,772

 

 

$

2.08

 

 

 

7.50

 

 

$

99,904

 

 

The weighted-average grant-date fair value of options granted during the three months ended March 31, 2021 and 2020 were $29.13 and $5.63 per share, respectively.

The aggregate intrinsic values of options outstanding and vested and exercisable were calculated as the difference between the exercise price of the options and the fair value of the Company’s common stock.

As of March 31, 2021, total unrecognized stock-based compensation related to outstanding unvested stock options was $17.9 million, which the Company expects to recognize over a remaining weighted-average period of 3.0 years.

Restricted stock units

Restricted stock units (“RSUs”) granted under the 2020 Plan are share awards that entitle the holder to receive freely tradable shares of the Company’s common stock upon vesting. RSUs cannot be transferred and the awards are subject to forfeiture if the holder’s service to the Company terminates prior to the release of the vesting restrictions. The fair value of the RSUs is equal to the closing price of the Company’s common stock on the grant date.

RSU activity for the three months ended March 31, 2021 is set forth below:

 

 

 

Number of

shares

 

 

Weighted average

grant date fair value

per share

 

 

 

 

 

 

 

 

 

 

Balance December 31, 2020

 

 

8,270

 

 

$

50.70

 

RSUs granted

 

 

245,030

 

 

 

54.17

 

Balance March 31, 2021

 

 

253,300

 

 

$

54.06

 

12


Eargo, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

 

 

Employee Stock Purchase Plan (ESPP)

In October 2020, the Board of Directors and stockholders adopted and approved the 2020 Employee Stock Purchase Plan (the “ESPP”). As of March 31, 2021, the Company reserved 1,109,239 shares of common stock for future issuance under the ESPP. The ESPP provides for consecutive, overlapping 24-month offering periods, which are generally divided into four purchase periods of approximately six months. The offering periods are scheduled to start on the first trading day on or after May 16 and November 16 of each year, with exception of the first offering period which commenced on October 16, 2020, the first trading day after the effective date of the Company’s registration statement, and will end on November 15, 2022. Contributions under the ESPP are generally limited to a maximum of 15% of an employee’s eligible compensation.

Each offering period consists of four six-month purchase periods. On each purchase date, which falls on the last date of each purchase period, ESPP participants will purchase shares of common stock at a price per share equal to 85% of the lesser of (1) the fair market value per share of the common stock at the start of the offering period or (2) the fair market value of the common stock on the purchase date.

The Company recorded $3.4 million of stock-based compensation related to the ESPP for the three months ended March 31, 2021. The fair value of the ESPP shares is estimated using the Black-Scholes option pricing model.

8. Net loss per share attributable to common stockholders

The following outstanding potentially dilutive common stock equivalents have been excluded from the computation of diluted net loss per share for the periods presented due to their anti-dilutive effect:

 

 

 

Three months ended March 31,

 

 

 

2021

 

 

2020

 

Convertible preferred stock

 

 

 

 

 

11,825,812

 

Common stock options issued and

   outstanding

 

 

6,319,155

 

 

 

3,483,384

 

Restricted stock units

 

 

253,300

 

 

 

 

Shares issuable pursuant to ESPP

 

 

176,867

 

 

 

 

Convertible preferred stock warrants

 

 

 

 

 

73,913

 

Total

 

 

6,749,322

 

 

 

15,383,109

 

 

 

 

13


 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and the related notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q, and for a full understanding of Eargo’s results of operations and financial condition, in conjunction with the consolidated financial statements and notes for the fiscal year ended December 31, 2020 contained in the Company’s Form 10-K filed on March 16, 2021. As a result of many factors, including those factors set forth in the “Risk factors” section of this Quarterly Report on Form 10-Q, our actual results could differ materially from the results described in or implied by these forward-looking statements. You should carefully read the “Risk factors” to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements.

Overview

We are a medical device company dedicated to improving the quality of life of people with hearing loss. We developed the Eargo solution to create a hearing aid that consumers actually want to use. Our innovative product and go-to-market approach address the major challenges of traditional hearing aid adoption, including social stigma, accessibility and cost.

We believe our Eargo hearing aids are the first and only virtually invisible, rechargeable, completely-in-canal, FDA regulated, exempt Class I or Class II devices for the treatment of hearing loss. Our rapid pace of innovation is enabled by our deep industry and technical expertise across mechanical engineering, product design, audio processing, clinical and hearing science, consumer electronics and embedded software design, and is supported by our strategic intellectual property portfolio.

We market and sell our hearing aids direct to consumers with a personalized, consumer-centric approach. Our commercial organization consists of a talented marketing team with deep experience in consumer-focused brand and performance marketing, a team of inside sales consultants, and a dedicated customer support team of licensed hearing professionals. We generate revenue from orders processed primarily through our website and over the phone by our sales consultants.

We believe that our differentiated hearing aids, consumer-oriented approach and strong brand have fueled the rapid adoption of our hearing aids and high customer satisfaction, as evidenced by over 68 thousand Eargo hearing aid systems sold, net of returns, as of March 31, 2021.

On October 20, 2020, we completed our IPO pursuant to which we sold an aggregate of 9,029,629 shares of our common stock resulting in net proceeds of $148.5 million after deducting underwriting discounts, commissions and offering expenses.

For the three months ended March 31, 2021, we generated net revenue of $22.0 million, an increase of $9.4 million from the three months ended March 31, 2020. To date, all our revenue has been generated from customers in the United States.

Our net losses were $13.6 million and $11.7 million for the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021, we had an accumulated deficit of $212.7 million. We expect to continue to incur losses for the foreseeable future.

Factors affecting our business

We believe that our future performance will depend on many factors, including those described below and in the section titled “Risk Factors” included elsewhere in this Quarterly Report on Form 10-Q.

Efficient acquisition of new customers

We have spent and expect to continue to spend significant amounts on sales and marketing designed to build a strong brand, achieve broad awareness of our Eargo solution, acquire new customers and convert sales leads. We have also invested and expect to continue investing in growing our teams of sales consultants and licensed hearing professionals to keep pace with increased demand, converting leads into satisfied customers and potentially growing our revenue.

Third-party payors

A significant portion of our revenue depends on payments from a concentrated number of third-party payors that we submit claims to on behalf of our customers. We expect to continue to focus substantial resources on both securing existing third-party reimbursement and increasing coverage and reimbursement for our current products and any future products we may develop. We are actively engaged in efforts to access the growing insurance coverage for hearing aids, including contracting or partnering with third-party payors, associations, and employers who offer hearing aid coverage to their members. Increasing the number of health plans we have access to would allow us to serve more customers who have access to some financial help paying for hearing aids.

14


 

Sales return rate

Our return policy allows our customers to return hearing aids for any reason within the first 45 days of delivery for a full refund, subject to a handling fee in certain states. The most commonly cited reason for returning our hearing aids is unsatisfactory fit, which we believe is a byproduct of our direct-to-consumer model and online distribution that results in nearly all of our customers ordering our product without trying it first. In addition to unsatisfactory fit, the next most cited reason for returns is that our hearing aids do not provide sufficient audio amplification. Customer return accrual rates were approximately 26% and 23% for the year ended December 31, 2020 and for the three months ended March 31, 2021, respectively. The decline in our sales return rate in 2020 and in the three months ended March 31, 2021 was a result of the growth in customers with health insurance coverage for hearing aids and repeat customers which have generally lower return rates than other customers, and our initiatives to improve customer service and enhance the quality of our pre-screening assessments. We report revenue net of expected returns, which is an estimate informed in part by historical return rates. As such, our return rate impacts our reported net revenue and profitability. If actual sales returns differ significantly from our estimates, an adjustment to revenue in the current or subsequent period is recorded.

New product introductions

Our technical capabilities and commitment to innovation have allowed us to deliver product enhancements on a rapid development timeline and support a compelling new product roadmap that we believe will continue to differentiate our competitive position over the next several years. With the launch of the Eargo Neo HiFi in January 2020, we have launched four generations of our hearing aids since 2017, with each iteration having improved audio performance, physical fit and/or comfort. We are focused on continuing to launch new versions of the Eargo hearing solution that further improve audio quality, fit, comfort and/or ease-of-use. We believe that the continued introduction of new products is critical to maintaining existing customers and increasing adoption of our solution, and as such, we expect to continue to invest in research and development to support new product introductions. In connection with our product innovation and iteration, we also need to successfully manage our product transitions to avoid delays in customer purchases, excess or obsolete inventory and increased returns as customers wait for our new products to become available. Our development priorities are focused, in part, on adding a refurbishment capability for returned hearing aids, which would allow us to refurbish and re-sell returned devices, which we anticipate would benefit our gross margin, although there is no guarantee that these efforts will succeed.

Seasonality

Prior to the effects of COVID-19, we have experienced and expect to continue to experience seasonality in our business, with higher sales volumes in quarters when we launch new products and in the fourth calendar quarter as a result of holiday promotional activity.

COVID-19 pandemic

We believe the COVID-19 pandemic thus far has largely resulted in favorable trends for our business. We believe that shelter-in-place restrictions and increased reluctance of consumers to be exposed to the virus, particularly among older consumers that comprise a majority of the population needing hearing aids, have increased customer interest to consider our vertically integrated telecare model. We believe our sales model can help consumers decrease their risk of potential exposure to COVID-19 by avoiding multiple trips to hearing aid clinics and close proximity to audiologists and other individuals at such clinics, which are part of the traditional hearing aid sales model.

Although we believe the COVID-19 pandemic has largely resulted in favorable trends for our business, we have experienced business disruptions, particularly at our California headquarters, where a majority of our employees have been working remotely. Moreover, travel restrictions, factory closures and disruptions in our supply chain could happen and we may not be able to obtain adequate inventory to sell.

The ongoing impact of COVID-19 depends on the duration and severity of the pandemic, which are difficult to assess or predict. While we have experienced growth in our sales volume during the COVID-19 pandemic, we cannot be certain whether we will maintain the current level of demand for our hearing aids. As a result, the impact of these or any future factors could be substantially different than what we have experienced to date. Please see the section titled “Risk Factors” for further discussion of the possible impact of the COVID-19 pandemic on our business.

Key business metrics

To analyze our business performance, determine financial forecasts and help develop long-term strategic plans, we review the following key business metrics, each of which is an important measure that represents the growth of our business:

 

Gross systems shipped. We define our gross systems shipped as the number of hearing aid systems shipped for which we recognized revenue during a reporting period.

15


 

 

Return accrual rates. Return accrual rates are determined by management at the end of each reporting period to estimate the percentage of returns made during a period. This determination is informed in part by historic actual return rates. Return accrual rates do not represent actual returns during a period as customers may return the product for a period of time that can extend beyond the period end, which can result in a hearing aid being returned after the period in which the revenue from its sale was recognized. If actual returns differ significantly from the return accrual rate determination made at period end, we may adjust revenue in subsequent periods to reflect the actual returns made. Such an adjustment to revenue will not result in an adjustment to the return accrual rate for the period.

The following table details the number of gross systems shipped and return accrual rates for the periods presented below:

 

 

 

Three months ended

 

 

 

March 31,

2020

 

 

June 30,

2020

 

 

September 30,

2020

 

 

December 31,

2020

 

 

March 31,

2021

 

Gross systems shipped

 

 

7,030

 

 

 

9,040

 

 

 

10,077

 

 

 

12,096

 

 

 

11,704

 

Return accrual rate

 

 

28.2

%

 

 

27.1

%

 

 

25.2

%

 

 

24.3

%

 

 

23.2

%

 

We believe these key business metrics provide useful information to help investors understand and evaluate our business performance. Gross systems shipped is a key measure of sales volume, which drives potential revenue, while return accrual rates are an indicator of potential reductions to revenue and an indicator of change in customer mix.

Components of our results of operations

Revenue, net

We generate revenue from the sale of Eargo hearing aid systems, accessories and extended warranties, with the majority of our revenue coming from sales of our Eargo hearing aid systems. We currently offer three versions of our hearing aid systems, the Eargo Max, the Eargo Neo and the Eargo Neo HiFi, at three different price points, and we periodically offer discounts and promotions. For product sales, control is transferred upon shipment to the customer. We report revenue net of expected returns, which is an estimate informed in part by historical return rates. Prior to January 2020, we also offered extended product warranties to our customers which covered the product for an additional year, commencing on the day after the initial one-year warranty expired. For extended warranty sales, control is transferred over time based on time elapsed throughout the extended warranty period.

Cost of revenue and gross margin

Cost of revenue consists of expenses associated with the cost of finished goods, freight, personnel costs, consumables, product warranty costs, transaction fees, reserves for excess and obsolete inventory, depreciation and amortization, and related overhead. We expect cost of revenue to increase in absolute terms as our revenue grows.

Our gross margin has been and will continue to be affected by a variety of factors, including sales volumes, product mix, pricing strategies, return accrual rates, costs of finished goods, product warranty claim rates and refurbishment strategies. We expect our gross margin percentage to increase over the long term to the extent we are successful in decreasing our rate of returns and implementing refurbishment programs after new product launches. Gross margin will likely fluctuate from quarter to quarter as we continue to introduce new products and adopt new technologies.

Research and development expenses

Research and development (“R&D”) expenses, consist primarily of engineering and product development costs to develop and support our products, regulatory expenses, non-recurring engineering and other costs associated with products and technologies that are in development, as well as related overhead costs. These expenses include personnel-related costs including salaries and stock-based compensation, supplies, consulting fees, prototyping, testing, materials, travel expenses, depreciation and allocated facility overhead costs. Additionally, R&D expenses include internal and external costs associated with our regulatory compliance and quality assurance functions, and related overhead costs. We expect R&D expenses, net of capitalized internal use software development costs, to increase in absolute dollars as we continue to develop new products and enhance existing products and technologies.

Sales and marketing expenses

Our sales and marketing expenses are the largest component of our operating expenses and consist primarily of personnel-related costs including salaries and stock-based compensation, direct marketing, advertising and promotional expenses, consulting fees, public relations costs and allocated facility overhead costs. Sales and marketing personnel include our inside sales consultants, licensed hearing professionals, marketing professionals and related support personnel. We expect our sales and marketing expenses to increase

16


 

in absolute dollars, but decrease over time as a percentage of revenue, as we hire additional sales and marketing personnel, expand our sales support infrastructure and invest in our brand and product awareness to further penetrate the U.S. market and potentially expand into international markets.

General and administrative expenses

Our general and administrative expenses consist primarily of compensation for executive, finance, legal, information technology and administrative personnel, including stock-based compensation. Other significant expenses include professional fees for legal and accounting services, consulting fees, recruiting fees, information technology costs, corporate insurance, bad debt expense, general corporate expenses and allocated facility overhead costs.

We expect to continue to incur additional general and administrative expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, and those of the Nasdaq Stock Market, additional insurance costs, investor relations activities and other administrative and professional services. As a result, we expect general and administrative expenses to increase in absolute dollars in future periods.

Interest income

Interest income consists of interest earned on cash and cash equivalents.

Interest expense

Interest expense consists of interest related to borrowings under our debt obligations and our convertible promissory notes prior to their redemption in July 2020.

Other income (expense), net

Other income (expense), net consists primarily of adjustments to the fair value of our convertible preferred stock warrant liabilities prior to their reclassification to additional paid in capital upon the closing of our IPO in October 2020.

Income tax provision

We use the asset and liability method to account for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to our historical operating performance and our recorded cumulative net losses in prior fiscal periods, our net deferred tax assets have been fully offset by a valuation allowance.

Financial statement effects of uncertain tax positions are recognized when it is more-likely-than-not, based on the technical merits of the position, that it will be sustained upon examination. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax.

17


 

Results of operations

Comparison of the three months ended March 31, 2021 and 2020

 

 

 

Three months ended

March 31,

 

 

Change

 

(dollars in thousands)

 

2021

 

 

2020

 

 

Amount

 

 

%

 

Revenue, net

 

$

22,048

 

 

$

12,669

 

 

$

9,379

 

 

 

74.0

%

Cost of revenue

 

 

6,297

 

 

 

4,656

 

 

 

1,641

 

 

 

35.2

 

Gross profit

 

 

15,751

 

 

 

8,013

 

 

 

7,738

 

 

 

96.6

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

4,778

 

 

 

2,809

 

 

 

1,969

 

 

 

70.1

 

Sales and marketing

 

 

16,855

 

 

 

10,859

 

 

 

5,996

 

 

 

55.2

 

General and administrative

 

 

7,487

 

 

 

6,078